Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 751-755

  Mgbonyebi, Ozuem P ^a   Russo, Jose ^a   Russo, Irma H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cell proliferation; Cyclin dependent kinase inhibitors; Roscovitine

Indexed keywords

ANTIMITOTIC AGENT; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; ESTROGEN RECEPTOR; PROTEIN KINASE; ROSCOVITINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CARCINOMA CELL; CELL COUNT; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; PURINES; TUMOR CELLS, CULTURED;

EID: 0031813095     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79: 551-555, 1994.
2. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994.
3. Hartwell LH, Kastan MB: Cell cycle and cancer. Science 266: 1821-1828, 1994.
4. Yang Z-H, Perkins ND, Ohno, T, Nabel EG, Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1: 1052-1056, 1995.
5. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH: A family of cdc2-related protein kinases. EMBO J 11: 2909-2917, 1992.
6. Van den Heuvel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054, 1993.
7. Morgan DO: Principles of CDK regulation. Nature 374: 1311-1314, 1995.
8. Karp JE and Broder S: Molecular foundations of cancer: New targets for intervention. Nature Med 1: 309-320, 1995.
9. Gorospe M, Liu Y, Xu Q, Chrest FJ and Holbrook NJ: Inhibition of G1 cyclin- dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 16: 762-770, 1996.
10. Sherr CJ and Roberts J: Inhibitors of mammalian G1 cyclindependent kinases. Genes and Dev 9: 1149-1163, 1995.
11. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications in human neoplasia. Am J Pathol 147: 545-560, 1995.
12. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6: 393-397, 1996.
13. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L. Shaw G and Strnad M: Cytokin- derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40: 408-412, 1997.
14. Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad, M and Kim S-H: Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243: 518-526, 1997.
15. Meijer L, Bordne A, Mulner O, Chong JPJ, Blow JJ, Inagaki M, Delcros J-G, and Moulinoux J-P: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536, 1997.
16. Rudolph B, Saffric JZ, Henglein B, Muller R, Ansorge W and Eilers M: Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A but not apoptosis. EMBO J 15: 3065-3076, 1996.
17. Soule HD, Vazquez J, Long A, Albert S and Brennan MJ: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1412, 1973.
18. Brooks SC, Locke ER and Soule HD: Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248: 6251-6253, 1973.
19. Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990.
20. Zhou J-N and Linder S: Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines. Anticancer Res 16: 1931-1936, 1996.
21. El-Diery W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer E, Kinzler K and Volgelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
22. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes and Dev 8: 9-22, 1994.
23. Ongkeko W, Ferguson DJP, Harris AL and Norbury C: Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. Cell Science 108: 2897-2904, 1995.
24. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzukitakahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y and Yasuda H: Butyrolactone-1, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432, 1993.